Molecular Structure:

Molecular Formula: C₅₃H₇₂N₂O₁₂
Molecular Weight: 929.1439
IUPAC Name: 5-[3-[1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
Synonyms of Atracurium (CAS NO.64228-79-1): BRN 1523633 ; UNII-2GQ1IRY63P ; Isoquinolinium, 1,2,3,4-tetrahydro-2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-2-methyl- ; Isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-
CAS NO: 64228-79-1
Product Categories: Cholinergic Agents ; Cholinergic Antagonists ; Drug / Therapeutic Agent ; Human Data ; Neuromuscular Agents ; Neuromuscular Blocking Agents ; Neuromuscular nondepolarizing agents ; Neurotransmitter Agents ; Nicotinic antagonists ; Peripheral Nervous System Agents
Melting point: 185-194 ºC

  Atracurium (CAS NO.64228-79-1) besylate was first synthesized in 1974 by George H. Dewar, a pharmacist and a medicinal chemistry doctoral candidate in John B. It is developed the drug (then known as BW 33A) and its introduction to first human trials in 1979, and then eventually to its first introduction (as a mixture of all ten stereoisomers) into clinical anesthetic practice in the UK, in 1983, under the tradename of Tracrium. Its limited clinical utility for the future was presaged with the marketing approval of cisatracurium in 1995 under the tradename of Nimbex.

  Atracurium (CAS NO.64228-79-1) isused adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.